FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GARDNER JASON					2. Issuer Name and Ticker or Trading Symbol Magenta Therapeutics, Inc. [MGTA]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	GENTA T	rirst) (HERAPEUTICS, Y SQUARE	Middle)		3. Date of Earliest Tran 06/20/2019				nsaction (Month/Day/Year)						_	cer (give title		Other (specify below)	
(Street)	IDGE M	IA (02139		4. If	Amen	dment,	Date	of Origi	inal Fil	led (Month/Da	ay/Year)		Line) 【 Forn	n filed by C	One Rep	ng (Check porting Per an One Re	son
(City)	(S		Zip)	lan Banka	- 4:	0					:	£ 5				1			
1. Title of Security (Instr. 3) 2. Transact Date		2. Transaction	on 2A. Deemed Execution Date,		ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 06			06/20/20)19			S ⁽¹⁾		1,669	D	\$15	.1	361,543			D			
Common	Stock			06/21/20)19				S ⁽¹⁾		12,331	D	\$15.1	L1 ⁽²⁾	349,212			D	
Common	Stock														292	2,990		I	By J.P. Gardner Irrevocable Trust
Common Stock														359,092			I	By P.S. Gardner Irrevocable Trust	
		Та	ıble II								posed of, convertib				Owned			,	
Security or Exercise (Month/Day/Year) if any		emed ion Date, I/Day/Year) 4. Transa Code (I				6. Date Exel Expiration I (Month/Day		Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (li	Price of erivative ecurity nstr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	e Ownersh s Form: Direct (D or Indirect g (I) (Instr.		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Codo	,,	(0)	(D)	Date	vicable	Expiration	Title	or Number of						

Explanation of Responses:

- 1. This trade is pursuant to an active 10b5-1 plan.
- 2. This transaction was executed in multiple trades at prices ranging from \$15.10 to \$15.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

President and Chief Executive Officer

/s/ Zo<u>ran Zdraveski, Attorney-</u> 06/24/2019 in- Fact for Jason Gardner

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.